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 Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and 
inflammation 
 
Abstract 
 
The metabolic actions of the ghrelin gene-derived peptide obestatin are still unclear. We investigated 
obestatin effects in vitro, on adipocyte function, and in vivo, on insulin resistance and inflammation in mice 
fed a high-fat diet (HFD). Obestatin effects on apoptosis, differentiation, lipolysis, and glucose uptake were 
determined in vitro in mouse 3T3-L1 and in human subcutaneous (hSC) and omental (hOM) adipocytes. In 
vivo, the influence of obestatin on glucose metabolism was assessed in mice fed an HFD for 8 wk. 3T3-L1, 
hSC, and hOM preadipocytes and adipocytes secreted obestatin and showed specific binding for the 
hormone. Obestatin prevented apoptosis in 3T3-L1 preadipocytes by increasing phosphoinositide 3-kinase 
(PI3K)/Akt and extracellular signal-regulated kinase (ERK)1/2 signaling. In both mice and human adipocytes, 
obestatin inhibited isoproterenol-induced lipolysis, promoted AMP-activated protein kinase 
phosphorylation, induced adiponectin, and reduced leptin secretion. Obestatin also enhanced glucose 
uptake in either the absence or presence of insulin, promoted GLUT4 translocation, and increased Akt 
phosphorylation and sirtuin 1 (SIRT1) protein expression. Inhibition of SIRT1 by small interfering RNA 
reduced obestatin-induced glucose uptake. In HFD-fed mice, obestatin reduced insulin resistance, increased 
insulin secretion from pancreatic islets, and reduced adipocyte apoptosis and inflammation in metabolic 
tissues. These results provide evidence of a novel role for obestatin in adipocyte function and glucose 
metabolism and suggest potential therapeutic perspectives in insulin resistance and metabolic 
dysfunctions. 
_______________ 
White adipose tissue (WAT) plays a key role in energy homeostasis and endocrine functions by secreting 
different hormones and adipokines influencing pathophysiological processes such as growth and 
differentiation, glucose homeostasis, and cancer (1). Increased WAT mass, as in obesity, is accompanied by 
chronic systemic inflammation, characterized by increased macrophage infiltration in WAT and elevated 
production of proinflammatory cytokines, both activating inflammatory pathways in adipocytes. The 
consequent changes in secretion of WAT-derived factors contribute to the development of obesity-
associated pathologies like insulin resistance and type 2 diabetes (T2D; refs. 2, 3). 
 
Obestatin is a 23-aa amidated peptide encoded by the ghrelin gene and mainly produced by the stomach. 
Obestatin was found to interact with the orphan receptor G-protein-coupled receptor 39 (GPR39) and to 
oppose the stimulatory effect of acylated ghrelin (AG) on food intake and gastrointestinal motility (4,–,6). 
However, different studies failed to confirm obestatin anorexigenic effects, as well as GPR39 binding 
capacity (7,–,9), and obestatin biological actions are still debated. 
 
Obestatin exerts both central and peripheral actions, including stimulation of cell survival and inhibition of 
apoptosis (10,–,12). Like AG and unacylated ghrelin (UAG), obestatin is mainly produced in the stomach, 
and at lower levels in the endocrine pancreas and different peripheral tissues (13,–,15). We have recently 
shown that obestatin exerts survival and antiapoptotic actions in pancreatic β cells and human pancreatic 
islets, regulates glucose-induced insulin secretion, and increases expression of key pancreatic genes (11). 
We have also suggested that obestatin may bind to the glucagon-like peptide 1 receptor (GLP-1R), which in 
turn would at least partly mediate the survival effects of the peptide in pancreatic β cells (11). Moreover, 
like ghrelin, obestatin prevents diabetes in streptozotocin-treated rats by improving glucose homeostasis 
and insulin secretion and increasing β-cell mass (16). Collectively, these findings strongly suggested a 
relevant metabolic role of the peptide. 
 
Concerning WAT, although obestatin binding to GPR39 remains highly debated, GPR39 mRNA expression 
has been shown in different tissues, including human WAT (6, 17, 18). Moreover, Zhang et al. (6) reported 
Ob binding to recombinant GPR39 and to different tissues and GPR39-expressing cells, including WAT. 
Recently, obestatin effects in adipocyte metabolism and differentiation have been shown in 3T3-L1 
adipocytes and rat adipose tissue (19, 20). However, knowledge on obestatin metabolic actions and its 
precise role in this context is still fragmentary and inconclusive and remains to be fully elucidated, 
particularly in primary human and mice adipocytes, as well as in whole metabolic function in an in vivo 
animal model. To circumvent this, we investigated the obestatin effects on adipocyte function in vitro, in 
both mice and human adipocytes, and examined its role on glucose metabolism and inflammation in vivo in 
mice fed a high-fat diet (HFD). 
MATERIALS AND METHODS 
Reagents 
Human and mouse obestatin, mouse AG, and UAG were from Phoenix Pharmaceuticals (Karlsruhe, 
Germany). Insulin-like growth factor-I (IGF-I), human insulin, PD-98059, wortmannin, Hoechst-33258, 
isoproterenol (ISO), dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), type 2 collagenase, bovine 
albumine, pantothenic acid, transferrin, biotin, 2-deoxi-d-glucose, Oil Red O, NH4CI, KHCO3, EDTA, and 
mammalian cell lysis kit were from Sigma-Aldrich (Milan, Italy). [3H]-2-deoxy-d-glucose was from Perkin 
Elmer Life Sciences (Boston, MA, USA). Cell culture reagents and AlexaFluor-labeled antibodies were from 
Invitrogen (Milan, Italy). P-Akt (Ser473) and P-extracellular signal-regulated kinase (ERK) antibodies were 
from Cell Signaling Technology (Celbio, Milan, Italy). ERK1/2, Akt, and GLP-1R antibodies were from Santa 
Cruz Biotechnology (DBA, Milan, Italy). Antibodies against P-AMP-activated protein kinase (P-AMPK; 
recognizing both α1 and α2 P-AMPK on T172), AMPK, sirtuin 1 (SIRT1), β-actin, glucose transporter type 4 
(GLUT4), and GPR39 were from Abcam (Cambridge, UK). Horseradish peroxidase-conjugated secondary 
antibodies were from Bethyl Laboratories (Tema Ricerca, Bologna, Italy). ECL reagent was from Perkin 
Elmer Life Sciences. RT-PCR reagents were from PE Applied Biosystems (Milan, Italy). 
Isolation and differentiation of human adipocytes 
Subcutaneous (SC) and omental (OM) fat tissue was obtained during laparoscopic surgery for nonmalignant 
diseases from 35 obese nondiabetic and 6 lean adult subjects, who had given informed consent before 
surgery. The study protocol was approved by the local ethics committee (Department of Internal Medicine, 
University of Turin). Adipocyte isolation was performed as described previously (21). At confluence, 
preadipocyte culture medium was changed to DMEM (Life Technologies; Invitrogen) containing 10% FBS, 
15 mM HEPES, 33 μM biotin, 17 μM pantothenate, 10 μg/ml transferrin, 5 μg/ml human insulin, 1 μM 
dexamethasone, and 0.5 mM IBMX for 3 d to initiate differentiation. At d 4, dexamethasone and IBMX were 
removed from the medium; cells were refed every 3 d and harvested at d 0, 7, 14, and 21 of differentiation. 
Preadipocytes maintained in DMEM/F12 supplemented with 10% FBS were used as controls. 
3T3-L1 cell culture 
3T3-L1 preadipocytes (ATCC, Manassas, VA, USA) were maintained in DMEM supplemented with 10% FCS. 
At 2 d after confluence (d 0), cells were treated with differentiation medium (DM; 5 μg/ml insulin, 1 μM 
dexamethasone, and 0.5 mM IBMX) in DMEM supplemented with 10% FBS. At 2 d after treatment, cells 
were maintained in DMEM supplemented with 10% FBS and 1 μg/ml insulin for up to 8 d, with a medium 
change every 2 d. 3T3-L1 differentiation was monitored by visualizing lipid droplets under light microscopy 
stained with 5% Oil Red O in 60% ISO. 
Imaging and flow cytometric analysis of obestatin binding and expression 
3T3-L1 and human preadipocytes were grown on coverslips up to 50–60% confluence. A labeled obestatin 
derivative, TAMRA-obestatin (Inbios, Naples, Italy), was used to visualize obestatin binding sites. TAMRA-
obestatin specificity toward obestatin binding sites was tested in competition experiments. Obestatin 
binding on 3T3-L1 preadipocytes and adipocytes (d 8) was assessed by exposing the cells to 1.5 μM TAMRA-
obestatin in serum-free DMEM at 37°C for 20 min after 10 min of preincubation at 4°C, when unlabeled 
obestatin (from 10 nM to 2 μM) or unrelated competitors (1 μM) were added. Cells were subsequently 
washed in PBS, fixed in 3% paraformaldehyde, and processed for microscopy. TAMRA-obestatin-specific 
binding to human subcutaneous (hSC) preadipocytes was tested as described for 3T3-L1. Confocal 
microscopy analysis was performed using a Zeiss LSM 5 Pascal Model Confocal Microscope (Carl Zeiss 
International, Oberkochen, Germany). For flow cytometric analysis, cells were analyzed using a FACSCanto 
and Diva software (Beckton Dickinson, Franklin Lakes, NJ, USA). Ten thousand events were analyzed for 
each sample. Obestatin protein expression was determined by immunofluorescence in normal hSC and 
human omental (hOM) tissue, both obtained from surgical specimens of patients who underwent surgery 
for nontumoral diseases. Tissues were fixed and stained using a rabbit obestatin polyclonal antibody 
(diluted 1:300; Phoenix Pharmaceuticals), followed by FITC-conjugated goat anti-rabbit antibody (diluted 
1:200; Abcam). 
RT-PCR and real-time PCR 
Total RNA extraction from 3T3-L1, hSC, and hOM adipocytes and reversed transcription to cDNA from 3 μg 
RNA were performed as described previously (22). RT-PCR primers were synthesized by TibMol Biol (Genoa, 
Italy) and Tema Ricerca (Bologna, Italy). The following primer sequences were used: mouse GPR39, Fwd 5′-
CCCTATAACACAGGCCCAGA-3′ and Rev 5′-CACCCAAAAGAACTCCCAGA-3′ (accession no. BC_085285); human 
GPR39, Fwd 5′-AGGTGCTGCAGAAGAAAGGA-3′ and Rev 5′-GCCTCGAAGAGGAAAGTGTG-3′ (accession no. 
NM_001508); 18S rRNA, Fwd 5′-GTGGAGCGATTTGTCTGGTT-3′ and Rev 5′-CGCTGAGCCAGTTCAGTGTA-3′ 
(accession no. X_01117); mouse SIRT1, Fwd 5′-GCTCGCCTTGCGGTGGACTT-3′ and Rev 5′-
TGGCTCATCAGCTGGGCACC-3′ (accession no. NM_019812.2). cDNA (9 μl) was amplified (GeneAmp PCR 
System; Perkin Elmer, Milan, Italy) in 50 μl under the following conditions: 94°C for 30 s, for 64°C for 30 s 
annealing; 72°C for 30 s, 72°C for 7 min. The final PCR products were separated by 1.5% agarose gel 
electrophoresis and visualized by ethidium bromide staining. For real-time PCR, the following primers were 
used: preproghrelin, Fwd 5′-CTGCTGATACTGAGCTCCTGACAG-3′ and Rev 5′-
AGGAGCTGGAGAGATCAGGTTCAAT-3′ (accession no. NM_021488.4); 18s rRNA, Fwd 5′-
CCCATTCGAACGTCTGCCCTATC-3′ and Rev 5′-TGCTGCCTTCCTTGGATGTGGTA-3′ (accession no. 
NR_003278.3). Real-time PCR was performed with 50 ng of cDNA, 150 nM of each primers, and a 2× Master 
Mix (annealing 61°C) using ABI-Prism 7300 (Applied Biosystems). 
GLUT4 immunofluorescence 
3T3-L1 cells were grown on glass coverslips and differentiated. On d 8, they were serum starved for 2 h at 
37°C and treated with either 100 nM insulin or 10 nM or 100 nM obestatin for 30 min and then washed 
twice with 1× PBS. The cells were then fixed with 4% paraphormaldeyde, permeabilized, and incubated 
with anti-GLUT-4 antibody. After being washed 3 times with 1× PBS, cells were incubated with AlexaFluor 
488-conjugated goat anti-mouse IgG (Invitrogen) for 1 h at room temperature. Cytoplasmic and surface-
membrane-bound GLUT-4 were visualized using confocal laser scanning microscopy (Leica TCS SP2). Nuclei 
were stained with DAPI. Fluorescence excitation was obtained at 488 nm via argon/krypton laser line for 
Alexa 488. DAPI was detected by Coherent Enterprise II 351/364-nm laser lines (Coherent Inc., Santa Clara, 
CA, USA). Green and blue channels were assigned to GLUT-4 and the nuclei, respectively. Single-labeled and 
negative (i.e., isotype-matched) controls were also analyzed. Cytoplasmic and surface-membrane-bound 
GLUT-4 were visualized using confocal laser scanning microscopy (Leica TCS SP2). 
Cell proliferation and survival 
3T3-L1 preadipocyte cell proliferation was assessed by bromodeoxyuridine incorporation ELISA (Roche, 
Indianapolis, IN, USA), as described previously (11). Cell survival was assessed by trypan blue exclusion on 
3T3-L1 preadipocytes. Cells were stained with trypan blue dye (0.04% w/v; Invitrogen). Viable (unstained) 
and nonviable (blue-stained) cells (300 cells/dish) were counted with a Countess automated cell counter 
(Invitrogen). 
Hoechst staining and caspase 3 activity 
Morphological changes in the nuclei of apoptotic preadipocytes were detected by Hoechst 33258, as 
described previously (11). Caspase 3 activity was assessed by caspase-3 colorimetric kit (Assay Designs, 
Milan, Italy) in preadipocyte cell lysates, according to the manufacturer's instruction. 
Western blotting 
Immunoblot analysis were performed as described previously (11). Proteins were extracted from 3T3-L1 
and human adipocytes and from mouse soleus muscle, adipose tissue, and liver. Proteins (50 μg) were 
resolved in 10% SDS-PAGE and incubated with the specific antibody (P-ERK1/2, P-AKT, P-AMPK, SIRT1, and 
GLP-1R). Blots were reprobed with the respective total antibodies against or β-actin (for SIRT1 and GLP-1R) 
for normalization. Immunoreactive proteins were visualized with Chemidoc XRS (Bio-Rad, Milan Italy), and 
densitometric analysis was performed with Quantity One software (Bio-Rad). 
Protein secretion from adipocytes 
Obestatin secretion was assessed in concentrated (18-fold) culture medium from differentiating adipocytes 
(3T3-L1, hSC, and hOM) using the obestatin radioimmunoassay (RIA) kit (Phoenix Pharmaceuticals), 
following the manufacturer's instruction. Obestatin in cell culture medium (50 μl DMEM+10% FBS), either 
in the presence or absence of 3T3-L1 preadipocytes or adipocytes, was measured using the obestatin (rat 
and mouse) enzyme immunoassay (EIA) kit (EK-031-90; Phoenix Pharmaceuticals), following the 
manufacturer's instructions. Adiponectin and leptin secretion was evaluated in hSC adipocyte concentrated 
(18-fold) conditioned medium using the human and mouse adiponectin ELISA kit and the human leptin 
ELISA kit, respectively (R&D Systems, Minneapolis, MN, USA), following the manufacturer's instructions. 
tumor necrosis factor α (TNF-α) and interleukin-1β (IL1-β) were measured by specific ELISA kits 
(eBioscience, San Diego, CA, USA) and adiponectin quantified with the human and mouse adiponectin ELISA 
(R&D Systems). Briefly, mouse tissues (epididymal and SC adipose tissue, soleus muscle, and liver) were cut 
into small pieces and lysed with mammalian cell lysis kit (Sigma-Aldrich). Monoclonal antibodies specific for 
each cytokine were precoated onto microplates. Samples were then pipetted into the wells, and any 
cytokine present was bound by the immobilized antibody. After any unbound substances were washed 
away, an enzyme-linked polyclonal antibody specific for each cytokine was added to the wells. Following 
another wash, a substrate solution was added to the wells, the enzyme reaction was stopped with the 
addition of a stop solution, and the samples were quantified with a microplate reader. 
Triglyceride (TG) measurement 
TG content was determined using a colorimetric assay kit (Zen-Bio, Research Triangle Park, NC, USA) and 
normalized against total protein from each sample, determined by Bradford reagent (Sigma). 
Lipolysis assay 
Forty microliters of the floating fraction containing only differentiated adipocytes (for both 3T3-L1 and 
human adipocytes) was seeded into a 96-well plate, containing 100 μl of lipolysis assay kit buffer (Zen-Bio) 
in the presence or absence of either obestatin (1, 10 and 100 nM) or insulin (100 nM), as described 
previously (23). After 40 min, ISO (1 μM) was added to the wells, and incubation was carried out for a 
further 80 min. Following the manufacturer's instructions, 50 μl of medium was then transferred into a new 
96-well plate for glycerol measurement on a microplate reader at 570 nm (Eti System Fast Reader ELX; 
BioTek Instruments, Winooski, VT, USA). The amount of glycerol release was calculated as micromoles per 
milligram of protein and expressed as percentage of ISO-induced lipolysis. 
[3H]-2-deoxyglucose uptake 
Differentiated 3T3-L1 (d 8) and hSC adipocytes (d 21) were serum starved overnight at 37°C and then 
incubated with obestatin (10 or 100 nM), either with or without insulin (100 nM) for 20 min. Cells were 
then rinsed with glucose-free HEPES-buffered saline solution (140 mM NaCl, 20 mM HEPES/Na, 5 mM KCl, 
2.5 mM MgSO4, and 1 mM CaCl2 at pH 7.4) and incubated in the same buffer at 37°C for 10 min with 2 mM 
2-deoxyglucose containing 0.1 μCi/ml [3H]-2-deoxyglucose. Under these conditions, glucose uptake was 
linear for ≥20 min (data not shown). Uptake was stopped by rapid removal of the buffer, followed by 3 
washes in ice-cold PBS. Cells were solubilized by addition of 50 mM NaOH, and equal amounts of lysates 
were subjected to liquid scintillation counting (Beckman Instruments, Fullerton, CA, USA) to measure, in 
duplicate, cell radioactivity. Protein concentrations were determined using the BCA kit (Sigma-Aldrich). 
Uptake values, expressed as picomoles per minute of [3H]-2-deoxyglucose incorporated per milligrams of 
protein, were corrected for the non-carrier-mediated transport by measuring hexose uptake in the 
presence of 10 μM cytochalasin B (a potent inhibitor of facilitated glucose transport). The nonspecific 
association of deoxyglucose with the cells was typically <10% of the total uptake. 
Small interfering RNA (siRNA) 
siRNAs targeting mouse SIRT1 and GLP1-R mRNA were synthesized by Qiagen (Milan, Italy) using the SIRT1 
target sequence: 5′-CAGATTGTTATTAATATCCTT-3′, sense: 5′-GAUUGUUAUUAAUAUCCUUTT-3′, antisense: 
5′-AAGGAUAUUAAUAACAAUCTG-3′; GLP-1R target sequence: 5′-TAGGAACTCCAATATGAACTA-3′, sense: 5′-
GGAACUCCAAUAUGAACUATT-3′, antisense: 5′-UAGUUCAUAUUGGAGUUCCTA-3′; and the control 
nonsilencing siRNA (catalog no. 1022076). 3T3-L1 preadipocytes (2 d postseeding) and differentiated 
adipocytes (d 7) were transfected in Opti-MEM I reduced serum medium without antibiotics with 50 nM 
control, SIRT1, or GLP-1R siRNAs using Lipofectamine RNAiMAX (Invitrogen) as recommended by the 
manufacturer. The medium was replaced with normal growth medium containing insulin after 4 h. Cells 
were transfected again after 48 h for glucose uptake experiments. Efficiency of transfection was assessed 
by RT-PCR and Western blot. 
Animals 
Mouse procedures conformed to the U.S. National Institutes of Health Guide for Care and Use of 
Laboratory Animals, and all procedures were approved by the Animal Care and Use Committee of the 
University of Turin. Male C57BL6/J (7-wk-old) mice were purchased from Charles River Laboratories (Lecco, 
Italy) and maintained with a standard diet and tap water ad libitum for 1 wk. Then, mice were separated 
into 4 groups (n=14/group): mice fed a low-fat diet (LFD; 10% energy as fat) and intraperitoneally injected 
for 1 wk with either saline (group 1) or obestatin (group 2; 1 μmol/kg/d); or fed an HFD (60% energy as fat) 
and similarly injected with saline (group III) or obestatin (group IV) for 1 wk. LFD and HFD were formulated 
by Mucedola Srl (Settimo Milanese, Italy). Injections were repeated for 3 d at d 25 and at d 39. Animals 
were weighed 1×/wk and after 8 wk (56 d) were anesthetized with tribromoethyl alcohol (Avertin; 375 
mg/kg i.p.). Blood samples were collected from the heart, and plasma glucose levels were determined using 
a glucose analyzer. Blood was then centrifuged at 20,000 g for 2 min at 4°C and stored at ∼20°C until use. 
Pancreas, liver, muscle, epididymal, and SC adipose tissue were rapidly excised and weighed. Tissues were 
either frozen in liquid nitrogen or homogenized in 4 M guanidine isothiocyanate buffer or fixed in neutral 
buffered formalin for protein analysis or total RNA extraction or histological examination, respectively. 
Plasma and pancreatic insulin were assessed as described previously (16) using an RIA kit (DiaSorin, 
Saluggia, Italy) or an ELISA kit (Millipore, Bedford, MA, USA) (24). Plasma obestatin was measured using the 
obestatin (rat, mouse) EIA kit (EK-031-90; Phoenix Pharmaceuticals), following the manufacturer's 
instructions. TNF-α and IL1-β were measured by specific ELISA kits (eBioscience), and adiponectin was 
quantified with the human and mouse adiponectin ELISA (R&D Systems), following the manufacturer's 
instruction. Caspase-3 activity was assessed by caspase-3 colorimetric kit (Assay Designs) in adipose cell 
lysates, as previously reported (11). In a second group of mice (n=5–10 mice/group), a glucose tolerance 
test (GTT; glucose 1 g/kg i.p.; overnight unfed condition) and insulin tolerance test (ITT; insulin 0.75 U/kg; 
fed condition) were performed in LFD- and HFD-fed control and obestatin-treated mice, as previously 
reported (24). Glucose levels were assessed by Glucocard G glucometer (Arkray, Kyoto, Japan) before 
injection (t0) and 15, 30, 60, and 120 min after injection of glucose or insulin. Circulating insulin levels, 
assessed by ELISA (Millipore) were compared between LFD- and HFD-fed control and obestatin-treated 
mice at t0 and t30 of the GTT. Circulating obestatin levels were measured with the mouse ELISA kit 
(Phoenix pharmaceuticals). Food intake was measured daily during the week before euthanasia, and energy 
intake was calculated based on diet composition. Morphometric analysis was performed using a digital 
microscope (DMD108; Leica MicroSystems) and included the evaluation of the mean islet area (evaluated in 
up to 10 islets for each case) and the number of epididymal or SC adipocytes, calculated as the mean 
number of adipocytes counted in 3 randomly selected fields viewed at ×400. 
Quantification of pancreatic insulin content 
Pancreas was homogenized and centrifuged in 5 ml acid-ethanol [0.15 M HCl in 75% (v/v) ethanol] at 1000 
g for 20 min; the supernatants were stored at −80°C, and the insulin was then quantified by RIA (DiaSorin) 
and normalized to milligrams of total protein (25). 
Quantification of insulin release from mouse pancreatic islets 
Glucose-stimulated insulin release from mouse pancreatic islets was assessed as described previously (26). 
Briefly, freshly removed pancreas was trimmed of adherent fat and connective tissue and minced into 
pieces of ∼40 mg. The pieces were washed in 15 ml polypropylene tubes containing 1 ml of Krebs buffer to 
dilute digestive hormones and preincubated for 30 min at 37°C. The buffer was then carefully drained, and 
the specimens were further incubated 1 h in either the absence or presence of different concentrations of 
glucose (2.8, 8.3, and 16.7 mM). The tissues were then pelleted, and the supernatants were collected and 
stored at −80°C. Insulin release in the supernatant was quantified by RIA (DiaSorin) and normalized to 
milligrams of total protein. 
Isolation of mouse adipocytes 
After excision, 500 mg of SC or eipididymal adipose tissue was cut into small pieces and digested at 37°C for 
2 h in DMEM with 1 mg/ml of type 2 collagenase (Sigma-Aldrich). Mature adipocytes were isolated as 
described previously (21). 
Glucose uptake in mouse WAT explants 
[3H]-2-deoxyglucose uptake in mouse epididymal adipose tissue was determined immediately after death, 
as described previously (27, 28). Adipose tissue (50 mg) was preincubated for 10 min at 37°C in 1 ml of 
Krebs-Ringer-HEPES (KRH) buffer (50 mM HEPES, pH 7.4; 137 mM NaCl; 4.8 mM KCl; 1.85 mM CaCl2; and 
1.3 mM MgSO4), also used for subsequent incubations. Incubation with or without 100 nM insulin was 
carried out at 37°C for 10 min. A stop solution and 2 washes in ice-cold KRH buffer were used to remove 
unbound [3H]-2-deoxyglucose and to block glucose transport. To facilitate measurement of the 
incorporated radioactive deoxyglucose, tissues were further dissolved in collagenase (1 mg/ml; Sigma-
Aldrich) at 37°C for 20 min and homogenized by tissue lyser (120 V, 50/60 Hz, 5 min; Qiagen). Data were 
expressed as picomoles per minute of [3H]-2-deoxyglucose incorporated per milligrams of tissue (wet 
weight). Nonspecific binding was determined under the same conditions in the presence of 50 μM 
cytocalasin B. 
Lipolysis assay in mouse WAT explants 
Mouse epididymal adipose tissue was cut into small pieces (300 mg), transferred into 15-ml tubes, and 
digested at 37°C for 2 h in DMEM with 1 mg/ml type 2 collagenase (Sigma-Aldrich). After the first 
centrifugation, the mature adipocytes formed a floating ring that was then collected and transferred into 2-
ml tubes. After additional washing and centrifugation steps, 40 μl of the floating fraction containing only 
mature adipocytes was seeded into a 96-well plate containing 100 μl of lipolysis assay kit buffer (Zen-Bio). 
Following the manufacturer's instructions, 50 μl of medium was transferred into a new 96-well plate, and 
the detection of glycerol amount was assessed by spectrophotometry at 570 nm absorbance using a 96-
well plate reader (Eti System Fast Reader ELX), calculated as micromoles per milligram of protein and 
expressed as a percentage of ISO-induced lipolysis. 
Statistical analysis 
Results are presented as means ± se. Calculations were performed using GraphPad Prism 5.0 software 
(GraphPad Software, San Diego, CA, USA). Statistical analyses were performed with Student's t test for 
independent samples or by 2-way ANOVA followed by Newman-Keuls post hoc test for multiple group 
comparisons. Significance was established as a value of P < 0.05. 
RESULTS 
Obestatin binds to and is secreted from 3T3-L1 cells and human adipocytes 
Confocal microscopy analysis in either the presence or absence of fluorescent TAMRA-obestatin was 
performed to investigate obestatin binding to 3T3-L1 and hSC preadipocytes, maintained 2 d in DM. Binding 
of TAMRA-obestatin was evidenced in both 3T3-L1 and hSC preadipocytes and was displaced in a dose-
dependent manner by unlabeled obestatin (10 nM to 2 μM), but not by BIM23627, a type 2 somatostatin 
receptor antagonist used as negative control (Fig. 1A, B). Complete displacement by unlabeled obestatin at 
concentrations equal or higher than 100 nM demonstrated high affinity of TAMRA-obestatin for obestatin-
binding sites (Fig. 1A, B). Human SC preadipocytes maintained in non-DM showed obestatin-binding 
capacity (Supplemental Fig. S1A). We previously showed partial obestatin binding to the GLP-1R in 
pancreatic β cells (11). Here, TAMRA-obestatin was displaced by the GLP-1R agonist exendin-4 (Ex-4) and by 
the antagonist exendin-9 (Ex-9) in both 3T3-L1 and hSC adipocytes (Fig. 1A, B). These results suggested 
specific obestatin interaction with GLP-1R in adipocytes. In further support of this assumption, obestatin 
binding in 3T3-L1 preadipocytes was prevented by siRNA against GLP-1R (Fig. 1A), which reduced GLP-1R 
protein expression by ∼40% (Fig. 1C) but not by control siRNA. Similar results were obtained in 
differentiated 3T3-L1 adipocytes (Supplemental Fig. S1C, D). 
Figure 1. 
 
Figure 1. 
 
Obestatin binding and secretion in 3T3-L1 and human preadipocytes. A) a–h) Confocal 
microscopy analysis of 3T3-L1 cells incubated for 48 h in DM in either the absence 
(control; a) or presence of TAMRA-obestatin (T-obe; 1.5 μM; b–h). Binding of TAMRA-
obestatin is shown in red, and nuclei are stained in blue (DAPI). c–f) Displacement of 
TAMRA-obestatin with increasing concentrations of unlabeled obestatin: 10 nM (c), 100 
nM (d), 1 μM (e), 2 μM (f). g, h) Displacement of TAMRA-obestatin binding with Ex-4 (g) 
or Ex-9 (h). i) BIM23627 was used as negative control for TAMRA-obestatin 
displacement. j, k) Inhibition of TAMRA-obestatin binding by siGLP1-R (k) but not by 
siControl (j). View: ×40. B) a–i) Confocal microscopy analysis of hSC preadipocytes 
incubated in either absence (control; a) or presence of 1.5 μM TAMRA-obestatin (b–i). 
c–f) Displacement of TAMRA-obestatin binding with increasing concentrations of 
unlabeled obestatin: 10 nM (c), 100 nM (d), 1 μM (e), 2 μM (f). g, h) Displacement of 
TAMRA-obestatin binding with Ex-4 (g) or Ex-9 (h). i) BIM23627 (1 μM) was used as 
negative control. View: ×100. C) GLP-1R protein expression, assessed by Western blot in 
3T3-L1 preadipocytes after 48 h transfection with either siControl or siGLP-1R. Blots 
were reprobed with anti-β-actin antibody. Graphs represent the densitometric analysis 
of GLP-1R normalized to β-actin and reported as percentage of siControl (n=3). Data are 
means ± se of 3 independent experiments. **P < 0.01. D) GLP-1R mRNA, assessed by RT-
PCR in 3T3-L1 adipocytes at the indicated days of differentiation, in the absence or 
presence of obestatin (10 nM). Results normalized to 18S rRNA transcript are expressed 
as percentage of control (d 0; n=3). Data are means ± se of 3 independent experiments. 
*P < 0.05, **P < 0.01. E) Obestatin secretion from 3T3-L1, hSC, and hOM adipocytes at 
the indicated days of differentiation. *P<0.05; **P<0.01 vs. d 0. F) Obestatin protein 
expression in hSC and hOM adipocytes, assessed by fluorescence microscopy (×100 
view; n=3). 
 
GLP-1R mRNA expression was determined during differentiation of 3T3-L1 adipocytes that were either 
untreated or treated with obestatin. GLP-1R mRNA in untreated cells increased at d 4 as compared with d 0 
and was further up-regulated at the end of differentiation (d 8). Obestatin did not influence GLP-1R 
expression at any day of differentiation (Fig. 1D). 
 
Flow cytometry analysis indicated that in 3T3-L1 preadipocytes, both the mean fluorescent index and the 
percentage of ligand-bound fluorescent cells increased with 1.5 μM and even more with 2 μM TAMRA-
obestatin. In hSC preadipocytes, TAMRA-obestatin binding peaked at 1.5 μM and decreased at 2 μM, 
suggesting saturation of obestatin binding sites (Supplemental Fig. S1B). 
 
Obestatin secretion in preadipocyte culture medium (d 0) increased at d 4 of differentiation in 3T3-L1 cells, 
at d 14 and 21 in hSC, and at d 21 in hOM adipocytes (Fig. 1E). Obestatin was not detected in cell-free DM, 
indicating exclusive production by adipocytes (data not shown). Obestatin in human adipocytes was further 
demonstrated by immunofluorescence staining, showing diffused cytoplasmic distribution (Fig. 1F). 
Obestatin prevents apoptosis of 3T3-L1 preadipocytes through phosphoinositide 3-kinase (PI3K)/Akt and 
ERK1/2 signaling 
 
Based on the previously observed antiapoptotic actions (11), we appraised the potential obestatin 
inhibitory effects against serum starvation-induced apoptosis in 3T3-L1 preadipocytes. Apoptosis increased 
under serum deprivation and was inhibited by IGF-I, which was used as control peptide (Fig. 2A, B). 
Similarly, IGF-I increased cell survival, which was strongly reduced by serum starvation (Fig. 2C). Obestatin 
had no effect at the lower concentrations tested (1 and 10 pM), whereas it reduced the percentage of 
apoptotic nuclei at the highest concentrations (100 pM to 100 nM; Fig. 2A). Moreover, obestatin reduced 
caspase-3 activity at all the concentrations tested in the nanomolar range (Fig. 2B) and increased cell 
survival (Fig. 2C). These effects were equal to or even stronger than those of IGF-I, particularly at 10 and 
100 nM. Peptide 14-1, the inverse sequence of UAG fragment 1-14, used as negative control, showed no 
survival or antiapoptotic effect. 
Figure 2. 
 
Figure 2. 
Obestatin antiapoptotic effects in 3T3-L1 preadipocytes. A–C) Cells were cultured in the 
presence of serum (s) or in serum-free medium (SF) for 48 h, either with or without 
obestatin (Obe), at the indicated concentrations, peptide 14-1 (10 nM) or IGF-I (10 nM). 
A) Apoptosis measured by counting fragmented/condensed Hoechst-stained nuclei. 
Values are expressed as percentage of apoptotic cells obtained from duplicate 
determinations (500 cells each, n=3). Top panel: Hoechst 33258 nuclear 
immunofluorescence staining (×200). Obestatin was used at 10 nM. Inset: cells cultured 
with serum; arrows, apoptotic cells. B) Caspase-3 activity, expressed as percentage of 
control (c, SF; n=3). C) Cell survival assessed by trypan blue assay. Data, expressed as 
percentage of control (c, SF), are from 8 replicates (n=3). D, E) Akt (D) and ERK1/2 (E) 
phosphorylation, assessed by Western blotting on lysates from 3T3-L1 preadipocytes 
stimulated with 10 nM obestatin for the indicated times in SF medium (top panels). 
Equal protein loading was determined by reprobing with antibodies to the respective 
total proteins (bottom panels). Graphs represent the densitometric analysis of 
phosphorylated proteins normalized to total proteins and reported as percentage of 
basal (n=3). F) Apoptosis, assessed by Hoechst staining (48 h) in SF medium in the 
presence or absence of 10 nM obestatin and either PD98059 (40 μM) or wortmannin 
(WM; 100 nM). *P < 0.05, **P < 0.01, ***P < 0.001 vs. SF (A) control (B, C), or basal (D, 
E). 
 
Next, we determined the involvement of the survival pathways PI3K/Akt and ERK1/2 in obestatin 
antiapoptotic effects. Based on the previous results, 10 nM was chosen as the best concentration for these 
experiments. Obestatin increased Akt phosphorylation at 10 min, peaking at 15 min and declining 
thereafter (Fig. 2D). ERK1/2 phosphorylation peaked at 5 min and then decreased, although it was up-
regulated for up to 60 min (Fig. 2E). Obestatin antiapoptotic action was reduced by PD98059 and 
wortmannin, the specific ERK1/2 and PI3K/Akt inhibitors, respectively (Fig. 2F). 
Obestatin effects on adipocyte differentiation 
 3T3-L1 preadipocytes were incubated with either control medium or DM in the absence or presence of 
obestatin for up to 8 d. At d 4, and particularly at d 8, lipid accumulation and size and number of lipid 
droplets increased in DM with respect to control medium, as determined by enhanced TG content and Oil 
Red O staining, respectively. Obestatin significantly increased lipid content in DM at d 8 but not at d 4 or in 
control medium (Fig. 3A). 
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Obestatin effects on adipogenesis of 3T3-L1 and human adipocytes. A) Two-day 
postconfluent 3T3-L1 preadipocytes were incubated for up to 8 d with either control 
medium or DM for induction of adipogenesis in either the absence or presence of 
obestatin (10 nM; d 0, cells in DM medium). TG content was measured at the indicated 
days using a colorimetric assay kit, as described in Materials and Methods, and 
expressed as percentage of control, d 4 (−obestatin). Right panel: representative Oil Red 
O staining of 3T3-L1 cells at the indicated days of differentiation in the absence or 
presence of obestatin (10 nM; ×40). B) hSC preadipocytes were grown to confluence and 
then treated without (c) or with DM for the indicated days for up to 21 d in either the 
absence or presence of obestatin (10 nM). TG content is expressed as percentage of 
control, d 7 (−obestatin). Right panel: Oil Red O staining of hSC at different days of 
differentiation either with or without obestatin (10 nM; ×40). C, D) TG content in human 
OM adipocytes obtained from lean (C) or obese (D) nondiabetic individuals. OM 
preadipocytes were grown to confluence and then treated as for hSC (B). Results are 
expressed as percentage of control, d 7 (−obestatin) and are means ± se of values 
obtained from cells cultured from 6 different individuals. *P < 0.05, **P < 0.01; ns, not 
significant. 
 
Similarly, undifferentiated hSC adipocytes (d 0) had minimal TG stores and lipid droplets, which 
progressively increased up to d 21. Obestatin increased lipid content at d 7 and 14 in DM but not at d 21; 
no effect was observed in nondifferentiating control medium (Fig. 3B). 
 
The obestatin adipogenic effect was also determined in hOM adipocytes obtained from both lean and 
obese individuals. As for hSC, hOM preadipocytes were cultured in DM for up to 21 d. In OM cells from lean 
individuals, obestatin showed no effect at any of the days examined (Fig. 3C). Conversely, in those from 
obese individuals, obestatin increased TG content at both d 14 and 21 in DM (Fig. 3D). No effect was 
observed in control medium from hOM cells derived from either lean or obese individuals. 
Obestatin inhibits lipolysis in 3T3-L1 and human adipocytes 
 
To assess the lipolytic effects of obestatin, differentiated 3T3-L1 cells and hSC and hOM adipocytes were 
treated either without or with ISO in the absence or presence of obestatin or insulin that was used as 
antilipolytic control peptide. Lipolysis was measured by the content of glycerol released in the culture 
medium. As expected, ISO increased lipolysis in both 3T3-L1 and human adipocytes, whereas insulin 
reduced lipolysis in both basal and ISO-stimulated conditions (Fig. 4A, D). In 3T3-L1 cells, obestatin had no 
effect on basal lipolysis; however, it reduced ISO-induced glycerol release, at both 10 and particularly 100 
nM, but not at 1 nM (Fig. 4A). Similarly, in hSC cells, obestatin inhibited ISO-induced lipolysis at both 10 and 
100 nM to a similar extent, whereas no effect was observed with 1 nM. In addition, at 100 nM, obestatin 
decreased basal glycerol release (Fig. 4B). In hOM adipocytes, obestatin showed similar antilipolytic effects 
at all concentrations tested in fat cells from both lean and obese individuals. In OM adipocytes from obese 
individuals, obestatin even inhibited basal lipolysis (at 10 and 100 nM; Fig. 4C, D). To determine whether 
the other products of the ghrelin gene, AG, and UAG would influence obestatin antilipolytic action, 3T3-L1 
adipocytes were coincubated with obestatin and with AG, UAG, or the 2 peptides together. Neither AG nor 
UAG, nor a combination of both, showed any effect on the antilipolytic effect of obestatin (Supplemental 
Fig. S2). 
 
Figure 4. 
 
Obestatin inhibits ISO-induced lipolysis in 3T3-L1 and human adipocytes. A–D) 
Differentiated 3T3-L1 (A), hSC (B), and hOM adipocytes from lean (C) or obese 
individuals (D) were incubated for 40 min either with or without obestatin (Obe) at the 
indicated concentrations or insulin (100 nM). Lipolysis was measured in the absence or 
presence of 1 μM ISO that was added for a further 80 min. Results are expressed as 
percentage of glycerol release in basal conditions (control; n=4). *P < 0.05, **P < 0.01 vs. 
control; #P < 0.05 vs. ISO; ns, not significant. E, F) AMPK phosphorylation, assessed by 
Western blot in differentiated 3T3-L1 (E) and hSC (F) adipocytes stimulated for the 
indicated times with obestatin (10 and 100 nM for 3T3-L1 and 10 nM for hSCs) in serum-
free medium. Graphs show the densitometric analysis of P-AMPK normalized to AMPK 
and reported as percentage of basal. *P < 0.05, ***P < 0.001. G, H) Adiponectin (G) and 
leptin (H) secretion in hSC adipocytes, assessed at the indicated days of differentiation in 
either absence or presence of obestatin (10 nM; n=4, triplicate determinations). *P < 
0.05. 
 
AMPK has been shown to antagonize ISO-induced lipolysis in both rodent and human adipocytes (29, 30); 
therefore, we hypothesized that obestatin would activate AMPK. In both 3T3-L1 and hSC adipocytes, 
obestatin increased AMPK activity, as determined by increased phosphorylation on Thr172. In 3T3-L1, 
phospho-AMPK was increased by 10 nM and even more by 100 nM obestatin in a time-dependent manner, 
starting at 15 min (with 100 nM only), peaking at 60 min, and declining thereafter (Fig. 4E); 10 nM, the 
lowest obestatin concentration showing the best antilipolytic effect, similarly increased phospho-AMPK in 
hSC adipocytes (from 30 to 90 min; Fig. 4F). 
 
Adiponectin and leptin were shown to exert either antilipolytic or lipolytic actions, respectively (31,–,33). 
Therefore, we tested obestatin effects on secretion of these adipokines in hSC adipocytes. Figure 4G, H 
shows that obestatin increased adiponectin secretion at d 7 and 14 of differentiation, whereas it inhibited 
that of leptin at d 7, 14, and 21. 
Obestatin promotes glucose uptake in 3T3-L1 and human adipocytes 
 
To assess obestatin effect on glucose uptake, 3T3-L1 and hSC adipocytes were incubated with obestatin in 
either absence or presence of insulin. As expected, insulin increased 2-deoxyglucose uptake with respect to 
control. Obestatin increased insulin-induced glucose uptake at 10 nM and particularly at 100 nM in both 
3T3-L1 and hSC cells. Furthermore, 100 nM obestatin stimulated glucose uptake even in the absence of 
insulin in both cell types, and in hSC cells this effect was equal to that of insulin (Fig. 5A). 
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Obestatin stimulates 2-[3H]-deoxyglucose glucose uptake in 3T3-L1 and hSC adipocytes. 
A) Differentiated 3T3-L1 and hSC adipocytes incubated in serum-free medium in the 
absence (control, c) or presence of insulin (ins; 100 nM), either with or without 
obestatin (Obe) at the indicated concentrations (n=4, duplicate determinations). **P < 
0.01 vs. control; ##P < 0.01 vs. ins; ns, not significant. B) Obestatin effects on GLUT-4 
accumulation in the plasma membrane. 3T3-L1 preadipocytes were differentiated in 
chamber slides and then probed for GLUT-4. Insulin was used at 100 nM. Cells were 
visualized by confocal microscopy (n=3; ×100). C–F) Akt phosphorylation (C, D) and SIRT1 
protein expression (E, F) assessed by Western blot in differentiated 3T3-L1 (C, E) and hSC 
adipocytes (D, F), stimulated for the indicated times with obestatin (10 and 100 nM for 
3T3-L1 and 100 nM for hSCs) in serum-free medium. Blots were reprobed with antibody 
to Akt for P-Akt and to β-actin for SIRT1. Graphs show the densitometric analysis of P-
Akt normalized to Akt and SIRT1 to β-actin and reported as percentage of basal (n=3). 
**P < 0.01, ***P < 0.001 vs. time 0. G) SIRT-1 mRNA assessed by RT-PCR in 3T3-L1 
adipocytes after 48 h transfection with either nonsilencing siRNA (siControl) or siRNA to 
SIRT1 (siSIRT1). As expected, the amplified products corresponded to 369 bp for mouse 
SIRT1, and 230 bp for β-actin that was used as internal control. H) SIRT1 protein 
expression assessed by Western blot in 3T3-L1 adipocytes after 48 h transfection with 
either siControl or siSIRT1. Blots were reprobed with anti-β-actin antibody. Graphs 
represent the densitometric analysis of SIRT1 normalized to β-actin and reported as 
percentage of siControl (n=3). **P < 0.01. I) Inhibition of obestatin-induced glucose 
uptake in 3T3-L1 adipocytes transfected with siSIRT1. 2-[3H]-deoxyglucose glucose 
uptake was assessed in siControl- or siSIRT1-transfected 3T3-L1 adipocytes incubated in 
serum-free medium (c) in the absence or presence of insulin (100 nM) and either with or 
without obestatin (100 nM; n=4). **P < 0.01, ***P < 0.001. 
 
GLUT-4 distribution was examined by confocal microscopy in differentiated 3T3-L1 adipocytes under basal 
and insulin- and obestatin-stimulated conditions. Compared with untreated cells, which demonstrated 
diffuse cytoplasmic staining, both insulin and obestatin independently induced GLUT-4 translocation on the 
cell membrane. Obestatin showed the best effect at 100 nM, where GLUT-4 translocation appeared to be 
slightly stronger than that induced by insulin at the same concentration, whereas at 10 nM the effect was 
lower (Fig. 5B). Similar results were obtained in hSC adipocytes (data not shown). 
 
Furthermore, obestatin increased Akt phosphorylation in either differentiated 3T3-L1 or hSC adipocytes. In 
3T3-L1 adipocytes, Akt phosphorylation increased at 15 min at both 10 and 100 nM obestatin and declined 
thereafter, being not significant at 90 min (Fig. 5C). In hSC adipocytes, 100 nM obestatin, the best 
concentration to promote glucose uptake, increased phospho-Akt from 15 up to 90 min (Fig. 5D). 
 
SIRT1 has been shown to exert anti-inflammatory effects and to increase glucose transport and insulin 
signaling in adipocytes (34). Therefore, we investigated SIRT1 involvement in obestatin-induced glucose 
uptake. Obestatin (100 nM) increased SIRT1 protein in 3T3-L1 adipocytes at 30 min; thereafter, both 10 and 
100 nM obestatin further up-regulated SIRT1 at 60 and 90 min (Fig. 5E). In hSC adipocytes, SIRT1 similarly 
increased from 30 to 90 min on obestatin stimulation (100 nM; Fig. 5F). To further assess the role of SIRT1 
in obestatin effects on glucose metabolism, we used siRNA targeted to SIRT1 in 3T3-L1 adipocytes. At 48 h 
after transfection, both SIRT1 mRNA and protein were reduced by siSIRT1 (40% for SIRT1 protein) 
compared with scrambled siRNA-transfected cells (control; Fig. 5G, H). SIRT1 knockdown decreased glucose 
transport in insulin-stimulated cells, and a similar effect was observed in the absence of insulin (control 
cells), whereas glucose uptake was lower. Obestatin-induced glucose uptake was reduced in siSIRT1 cells as 
compared with control siRNA both in the absence and, particularly, in the presence of insulin (Fig. 5I). 
Obestatin reduces insulin resistance in HFD-fed mice 
 
We next determined whether obestatin would improve the impaired insulin sensitivity induced by short-
term treatment with HFD. To this end, 8-wk-old mice were either untreated or intraperitoneally injected 
with obestatin and fed for 8 wk with HFD or LFD. Body weight was unchanged during HFD as compared 
with LFD feeding (Fig. 6A), likely because of the short duration of treatment, which mostly causes insulin 
resistance instead of obesity. Obestatin treatment did not influence body weight at the end of both diets. 
However, it reduced body weight to a limited extent in both LFD (wk 2 and 5 to 7) and HFD feeding (wk 1 
and 2; Fig. 6A). HFD feeding increased organ weight, particularly that of epididymal and SC adipose tissues, 
with respect to LFD. Obestatin did not influence tissue weight under either diet condition (Supplemental 
Fig. S2A). As previously shown (24), HFD-fed mice consumed more calories than LFD-fed mice; however, 
energy intake did not significantly differ between obestatin-treated and untreated mice across diets (Fig. 
6B). 
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Obestatin improves the metabolic profile of HFD-fed mice. Mice (8 wk old) were 
untreated or treated with obestatin (Obe) and fed with either LFD or HFD for 8 wk. A) 
Body weight measured at the indicated time points in mice fed an LFD (top panel) or an 
HFD (bottom panel) (n=14 mice/group). B) Energy intake. C) GTT in LFD (top panel) and 
HFD (bottom panels) control and obestatin-treated mice. D) Insulin levels under 
nonfeeding conditions, measured from tail vein blood samples collected at 0 and 30 min 
in GTT. E) Global area AUC for ITT based on absolute glucose levels (mg/dl; n=10 
mice/group). F) Plasma glucose, plasma insulin, and pancreatic insulin levels (n=6 
mice/group). G) Mean pancreatic islet area evaluated by morphometric analysis in ≥10 
islets/condition (n=6 mice/group). H) Glucose-induced insulin secretion during a 60-min 
incubation in pancreatic islets from LFD-fed mice (top panel) and HFD-fed mice (bottom 
panel) (n=6 mice/group). I) 2-[3H]-deoxyglucose uptake in epididymal fat explants (n=4 
mice/group). J) Lipolysis in epididymal fat explants assessed as glycerol release and 
expressed as percentage of control (LFD; n=4 mice/group). K) Mean number of 
adipocytes in epididymal (left panel) and SC (right panel) WAT (n=4 mice/group; ×400). 
L) Hematoxylin and eosin staining of epididymal or SC fat in mice fed an HFD, either 
untreated (vehicle) or treated with obestatin (n=4 mice/group). M) Caspase-3 activation, 
expressed as percentage of control (LFD) assessed in epididymal (left panel) and SC 
(right panel) fat (n=4). *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. 
 
To investigate the consequences of obestatin treatment on glucose homeostasis, GTTs and ITTs were 
performed in LFD- and HFD-fed control and obestatin-treated mice (Fig. 6C, E). Obestatin-treated mice 
displayed an improvement in the response to glucose and insulin, as glucose levels remained lower in 
obestatin-treated mice as compared with their control littermates at both 60 and 120 min postinjection in 
the LFD group and at 15 min in the HFD group. Area under the curve (AUC) values for ITT revealed better 
preservation of glucose tolerance of obestatin-treated mice in both LFD and HFD groups compared with 
controls (Fig. 6E), suggesting that obestatin improves insulin sensitivity (AUC for GTT, based on absolute 
glucose levels: for LFD-fed control vs. obestatin-treated mice, 20,010±1132 vs. 16,326±737 mg/dl, P<0.05; 
for HFD-fed control vs. obestatin-treated mice, 19,129±669 vs. 18,193±648 mg/dl). Measurement of insulin 
levels from tail-vein blood samples collected at 0 and 30 min after glucose injection in GTTs revealed that 
both LFD- and HFD-fed obestatin-treated mice secreted more insulin than control mice (Fig. 6D). 
 
Obestatin also prevented the negative effect of HFD on glucose homeostasis by reducing plasma glucose to 
levels comparable to those of LFD (Fig. 6F). Moreover, in HFD-fed mice, obestatin further enhanced plasma 
and pancreatic insulin, which were both increased in HFD-fed as compared with LFD-fed untreated mice. 
Obestatin even increased plasma but not pancreatic insulin in LFD-fed mice as compared with untreated 
mice (Fig. 6F). These results suggested direct insulinotropic effects of obestatin. Indeed, treatment with 
obestatin, besides counteracting HFD-induced reduction of islet area (Fig. 6G), strongly stimulated glucose-
induced insulin secretion in islets explanted from LFD- and, in particular, from HFD-fed mice, at all the 
glucose concentrations tested. Notably, in untreated mice, either basal or glucose-induced insulin secretion 
from islets was increased under HFD with respect to LFD feeding (Fig. 6H). 
 
These results, together with those obtained in 3T3-L1 and human adipocytes, prompted us to investigate 
the obestatin effect on glucose uptake and lipolysis in WAT from LFD- and HFD-fed mice. Figure 6I shows 
increased 2-deoxyglucose uptake in epididymal fat from obestatin-treated mice fed an HFD with respect to 
untreated animals, whereas no significant effect was observed in LFD-fed mice. Under insulin-stimulated 
conditions, glucose uptake increased in explants from both LFD- and HFD-fed mice. Moreover, in fat from 
obestatin-treated HFD-fed mice, glucose uptake was similar to that of untreated mice stimulated with 
insulin (Supplemental Fig. S2B). Treatment with obestatin also counteracted HFD-induced lipolysis, as 
assessed by reduced glycerol release from epididymal fat explants (Fig. 6J). 
 
To further assess the role of obestatin role on adipogenesis and inhibition of apoptosis, we determined 
adipocyte numbers and morphology, as well as apoptosis, in WAT explants from both LFD- and HFD-fed 
mice. HFD-fed mice displayed reduced adipocyte numbers in both epididymal and SC fat explants, as 
compared with LFD-fed mice (Fig. 6K). Obestatin treatment counteracted the effect of HFD by increasing 
adipocyte number but had no effect in LFD-fed mice. Accordingly, histological analysis indicated that 
epididymal and SC fat from HFD-fed mice displayed the expected enlarged, lipid-engorged adipocytes. In 
contrast, on obestatin treatment, HFD-fed mice showed increased adipocyte numbers with much smaller 
average cell sizes in both epididymal and, particularly, SC fat (Fig. 6L). 
 
In untreated mice, apoptosis increased in both epididymal and SC fat from HFD-fed mice, as assessed by 
increased caspase-3 activity. Obestatin counteracted HFD-induced apoptosis in both fat explants, 
particularly in SC fat (Fig. 6M). 
 
Obestatin levels in plasma from HFD- and LFD-fed mice were similar in both obestatin-treated and 
untreated animals, as assessed by ELISA (data not shown). Obestatin protein expression was also analyzed 
in tissues of mice fed a standard diet, being high in the stomach and low in epididymal and perirenal fat. 
Moreover, preproghrelin mRNA was highly expressed in the stomach of HFD-fed as compared with LFD-fed 
mice, whereas very low expression was found in adipose tissues under both diet conditions (Supplemental 
Fig. S3C, D). 
Obestatin reduces inflammation in HFD-fed mice 
 
Obestatin counteracted the inhibitory effect of HFD on adiponectin secretion by increasing adiponectin 
levels in both epididymal and SC adipose tissue (Fig. 7A, B). Moreover, obestatin increased adiponectin 
levels in SC fat from LFD-fed mice (Fig. 7B). The effects of obestatin on inflammatory cytokine production in 
adipose tissue, liver, and skeletal muscle of HFD-fed mice were also investigated. Figure 7A, B shows that 
obestatin reduced TNF-α and IL-1β levels in both epididymal and SC adipose tissue in HFD-fed mice, but not 
in LFD-fed mice. Similarly, obestatin reduced TNF-α in liver and muscle of HFD-fed mice and blocked IL-1β 
increase in the liver (Fig. 7C, D). Muscle IL-1β levels were unchanged in mice fed an HFD, and obestatin had 
no effect on IL-1β secretion in muscle (data not shown). 
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 Obestatin reduces inflammatory cytokine secretion and promotes Akt and AMPK phosphorylation in 
peripheral tissues of mice fed an HFD. Mice (8 wk old) were untreated or treated with obestatin (Obe) and 
fed with either LFD or HFD for 8 wk. A, B) Adiponectin, TNF-α, and IL-1β secretion from epididymal fat (A) 
and SC fat (B). C, D) TNF-α and IL-1β secretion from the liver (C) and TNF-α release from soleus muscle (D); 
n = 6 mice/group. E–L) Akt (E–H) and AMPK (I–L) phosphorylation (top panels) assessed by Western blot in 
epididymal fat (E, I), SC fat (F, J), soleus muscle (G, K), and liver (H, L). Blots were reprobed with antibodies 
to total proteins. Graphs represent the densitometric analysis of phosphorylated proteins normalized to 
total proteins and reported as percentage of LFD (n=3). *P < 0.05, **P < 0.01, ***P < 0.001; ns, not 
significant. 
Obestatin increases Akt and AMPK phosphorylation in metabolic tissues of HFD-fed mice 
 
Obestatin effects were next determined on Akt and AMPK activation in peripheral tissues. Akt 
phosphorylation on serine 473 was decreased in epididymal and SC fat of HFD-fed mice, with respect to 
LFD-fed mice (Fig. 7E, F). Conversely, phospho-Akt increased in muscle and liver of HFD-fed as compared 
with LFD-fed mice (Fig. 7G, H). Obestatin increased phospho-Akt in fat, muscle, and liver of HFD-fed mice 
(Fig. 7E–H) and in epididymal fat and liver of LFD-fed mice (Fig. 7E, H). Similarly, in fat, muscle, and liver, 
obestatin counteracted HFD-induced reduction of phopsho-AMPK and even increased phopsho-AMPK in 
LFD-fed mice (Fig. 7I–L). 
DISCUSSION 
 
This study shows that obestatin regulates adipocyte function and glucose metabolism. Obestatin, which is 
released by and binds to mouse and human adipocytes, inhibits preadipocyte apoptosis, counteracts ISO-
induced lipolysis, promotes glucose uptake and GLUT4 translocation, stimulates adiponectin, and inhibits 
leptin secretion. In HFD-fed mice, obestatin reduces insulin resistance and inflammation and activates key 
metabolic signaling pathways in WAT, liver, and muscle. 
 
WAT has a multifarious composition, comprising preadipocytes, adipocytes, macrophages, endothelial cells, 
fibroblasts, and leukocytes, which render this tissue an important mediator of metabolism and 
inflammation. Since the discovery of leptin, WAT has been recognized as an endocrine organ, secreting 
multiple adipokines, including hormone-like proteins and inflammatory cytokines (1,–,3). Many of these 
adipokines were originally described as being produced by tissues other than WAT. This is also the case of 
obestatin, which is mainly produced by the stomach but also the pancreas and other peripheral tissues (13, 
14). Here, we first show obestatin secretion from mouse 3T3-L1 and human SC and OM adipocytes in both 
undifferentiated and differentiated cells. This finding suggests that obestatin may be a novel adipokine, 
exerting either local autocrine/paracrine or distant endocrine effects. Adipokines, besides having broad 
actions in the body, regulate pancreatic β-cell function, including insulin secretion, gene expression, and 
apoptosis (35). Therefore, based on our present and previous findings in the endocrine pancreas (11, 16), it 
cannot be excluded that adipose tissue-derived obestatin may also influence pancreatic function. That 
adipocyte-derived obestatin may display autocrine/paracrine functions is also supported by previous 
studies showing that both inhibition of preproghrelin expression and neutralization of preproghrelin-
derived peptides, including obestatin, reduce adipocyte differentiation (20, 36). Here, the obestatin effect 
on adipocyte differentiation was less relevant, as compared with other functions, such as inhibition of 
lipolysis, induction of glucose uptake, regulation of β-cell function, or inhibition of inflammation. Therefore, 
the autocrine/paracrine functions of obestatin may be related to these aspects. Interestingly, obestatin 
protein and preproghrelin mRNA were found here to be expressed in mouse epididymal and subcutaneous 
adipose tissues, although their levels in fat were much lower than those in the stomach. Furthermore, 
preproghrelin mRNA expression in the stomach of HFD-fed mice was much higher than that of LFD-fed 
mice, consistent with previous studies (37, 38). 
 
That GPR39 is the obestatin receptor is still strongly debated (4, 7), and GPR39 expression in both mouse 
and human adipocytes has already been demonstrated (17, 20, 36). However, we previously suggested that 
obestatin at least partly interacts with GLP-1R in pancreatic β cells, which would explain to some extent its 
insulinotropic and survival effects (11). Here, obestatin binding to 3T3-L1 and human adipocytes was found 
displaced by the GLP-1R agonist Ex-4 and antagonist Ex-9; moreover, reducing the expression of GLP-1R in 
3T3-L1 preadipocytes and adipocytes by siGLP-1R prevented obestatin binding to these cells. Therefore, as 
for β cells, obestatin may trigger survival and metabolic signaling pathways through interaction with GLP-
1R. Consistently, recent findings have highlighted the role of GLP-1R in adipogenesis, adipocyte 
proliferation, and apoptosis (39), and GLP-1R mRNA expression was found here to increase during 
adipocyte differentiation. Conversely, obestatin showed no effect on GLP-1R expression. 
 
Obestatin binding in preadipocytes suggested effects in undifferentiated cells. Indeed, we first showed that 
obestatin prevents apoptosis and increases survival of 3T3-L1 preadipocytes. As for other cell types (10, 
11), obestatin antiapoptotic effects in preadipocytes involved activation of ERK1/2 and PI3K/Akt, which play 
a key role in adipocyte proliferation and survival (40,–,42). Adipocyte cell death is an event that may be 
enhanced by obesity or secondary to inflammation and macrophage infiltration (2, 3). Here, obestatin 
treatment in HFD-fed mice reduced WAT apoptosis, besides decreasing systemic inflammation. 
 
Adipose tissue remodeling is an ongoing physiological process involving both adipose cell apoptosis and 
adipogenesis. The latter implies the sequential induction of multiple transcription factors, acquisition of 
specific metabolic competences, and ability to produce and secrete fat-specific proteins. Deregulation of 
adipogenesis can contribute to obesity or lipodystrophy. However, adipocytes represent a safe place to 
store lipids, and enhanced adipogenesis, rather than being a cause of obesity, is the result of imbalance 
between energy intake and energy output (43). In the present study, obestatin enhanced TG content in 
differentiating 3T3-L1 and hSC adipocytes and increased adipogenesis in hOM adipocytes obtained from 
obese but not from lean individuals. OM fat, which mostly contributes to the pathogenesis of insulin 
resistance and T2D (44), is morphologically and functionally different from SC fat. Indeed, fat cells from 
different depots vary in size and responses to insulin and lipolytic agents, lipoprotein binding, fatty acid 
transfer, and production of secreted proteins (45). Such differences could contribute to the distinct effects 
of hormones on SC compared with OM fat. Here, adipogenesis was found to be greater in hSC than in hOM 
adipocytes, consistent with previous findings (46); similarly, the obestatin adipogenic effect was stronger in 
hSC than in hOM fat cells. Interestingly, AG and UAG were previously found to increase differentiation in 
3T3-L1 cells and cultured human adipocytes (41, 47), and obestatin showed similar effects in 3T3-L1 cells 
(19, 20), indicating adipogenic actions of all the ghrelin gene-derived peptides. 
 
Catecholamines are the most potent regulators of lipolysis in human adipocytes, and OM fat cells, 
particularly in obese individuals, have higher lipolytic activity than SC adipocytes, contributing to the 
increased free fatty acid levels in the systemic circulation (45). This is consistent with our present findings 
showing lower ISO-induced lipolysis in SC than in OM adipocytes; moreover, OM adipocyte lipolysis was 
reduced in obese with respect to lean individuals. Lipolysis is inhibited by insulin, which has a stronger 
effect in hSC than in hOM adipocytes (48). Obestatin was found here to inhibit ISO-induced lipolysis in both 
3T3-L1 and human adipocytes. Interestingly, like insulin, obestatin inhibited lipolysis even in the absence of 
ISO in both SC and OM adipocytes of obese individuals. Conversely, the other ghrelin gene-derived peptides 
ghrelin and UAG showed no effect on obestatin antilipolytic action, as indicated by coincubation 
experiments in 3T3-L1 adipocytes. In support of its antilipolytic role, obestatin also increased the 
phosphorylation of AMPK. This is an energy sensor that controls whole-body glucose homeostasis by 
regulating metabolism in peripheral tissues, and its activity has been shown to counteract ISO-induced 
lipolysis in both rodent and human adipocytes (29, 30). AMPK activation also increases glucose uptake and 
metabolism, fatty acid oxidation, and inhibition of hepatic lipogenesis and glucose production (49). 
Therefore, the finding that obestatin activates AMPK further substantiates its positive metabolic role. 
 
Obestatin increased adiponectin and reduced leptin secretion from hSC adipocytes. Notably, besides its 
insulin-sensitizing effects, adiponectin activates AMPK in metabolic tissues and inhibits adipocyte lipolysis 
(31). Conversely, leptin impairs insulin metabolic actions in adipocytes, i.e., stimulation of glucose 
transport, lipogenesis, and inhibition of ISO-induced lipolysis (32, 33). Overall, these results indicate that 
besides increasing adipogenesis, obestatin prevents lipolysis and acts similarly to insulin, although less 
potently; moreover, its actions in adipocytes at least partly resemble those of AG and UAG, which were 
found to increase adipogenesis in vivo and to inhibit ISO-induced lipolysis in vitro (50,–,52). 
 
With regard to glucose metabolism, we found that obestatin stimulated glucose uptake per se and 
enhanced the effect of insulin in both 3T3-L1 and hSC adipocytes. Interestingly, the obestatin effect was 
comparable to that of insulin when the peptides were used at equal concentrations in hSC adipocytes. In 
these experiments, only hSC cells were used, mainly because of the elevated number of cells required, 
which could not be obtained from small visceral biopsies. 
 
GLUT4 is the major insulin-responsive GLUT for insulin-dependent glucose disposal. Transgenic mice 
overexpressing GLUT4 in adipose tissue or skeletal muscle are highly insulin sensitive and glucose tolerant, 
whereas heterozygous GLUT4-knockout mice in muscle and adipose tissue show insulin resistance and 
diabetes (53). GLUT4 has an intracellular disposition in the unstimulated state and is redistributed to the 
plasma membrane in response to insulin and other stimuli (54). Here, obestatin promoted GLUT4 
translocation to the plasma membrane in 3T3-L1 adipocytes. This effect was at least as strong as that of 
insulin, suggesting that obestatin may influence GLUT4 translocation and glucose uptake independently of 
insulin. 
 We have recently demonstrated that obestatin induces Akt phosphorylation in pancreatic β cells and 
activates downstream targets of insulin (11). In adipocytes, PI3K/Akt activity is essential for insulin-
stimulated glucose transport and GLUT4 translocation to the cell membrane (42, 54). In the present study, 
obestatin per se stimulated Akt phosphorylation in mice and hSC adipocytes, further suggesting insulin-like 
effects. 
 
Activation of the NAD-dependent histone deacetylase SIRT1 in adipocytes increases glucose uptake and 
insulin signaling, reduces expression of inflammatory genes, and protects against HFD-induced metabolic 
damage (34, 55). Obestatin increased SIRT1 protein in both 3T3-L1 and hSC adipocytes, possibly acting as a 
SIRT1 activator. Moreover, SIRT1 knockdown in 3T3-L1 adipocytes strongly inhibited obestatin-induced 
glucose uptake, in either absence or presence of insulin, suggesting that SIRT1 is involved in obestatin-
induced glucose uptake. However, obestatin does not parallel all SIRT1 actions. Indeed, at variance with the 
obestatin adipogenic and antilipolytic effects, SIRT1 has been previously shown to repress differentiation 
and to stimulate lipolysis (56). Likely, in adipocytes obestatin activates additional signaling pathways or 
second-messenger cross-talk, similar to those observed in β cells (11). Moreover, obestatin and SIRT1 may 
influence the secretion of different adipokines, adding further complexity to the system. For instance, SIRT1 
stimulates adiponectin release, which in turn increases insulin sensitivity (56). 
 
Based on the observed insulin-like and insulin-sensitizing effects in adipocytes, we hypothesized that 
obestatin would exert protective effects against insulin resistance and inflammation in HFD-fed mice. Mice 
were fed an LFD or an HFD for 8 wk, which is sufficient for inducing insulin resistance, glucose intolerance, 
and inflammation (57, 58). Obestatin was claimed to exert anorectic effects, opposing the AG orexigenic 
actions (4); however, obestatin-induced inhibition of food intake has not been confirmed, and its role in 
feeding and body weight is still unclear (12). Here, treatment with obestatin slightly but not significantly 
reduced energy intake in both LFD and HFD feeding. Moreover, although obestatin decreased body weight 
to some extent in both diet groups, no difference was found between treated and untreated groups at wk 
8. These findings are consistent with recent studies showing no weight variation in HFD-fed rats treated 
with obestatin (59). 
 
In HFD-fed mice, obestatin treatment improved insulin sensitivity and reduced glucose intolerance, as 
suggested by the GTT and ITT results and by reduced plasma glucose levels. Interestingly, plasma insulin 
levels 30 min after a glucose bolus were significantly higher in obestatin-treated than in control mice, 
suggesting that β cells from obestatin-treated mice are more sensitive than those from control mice in 
response to a GTT. Moreover, the fact that the responses to ITT of both LFD and HFD obestatin-treated 
mice are significantly improved as compared with control mice (and as is clearly indicated by the AUC) 
suggests that obestatin improves insulin sensitivity. Furthermore, insulin levels after a glucose bolus at 30 
min were higher in mice treated with obestatin with respect to untreated mice in both diet conditions, 
likely explaining why obestatin-treated mice clear circulating glucose faster than controls in response to a 
GTT. 
 
These results, and the finding that obestatin further increased plasma and pancreatic insulin in HFD and 
even increased plasma insulin in LFD-fed mice, suggested insulinotropic effects of the hormone. Indeed, 
obestatin-treated mice showed increased insulin secretion in glucose-stimulated explanted islets from both 
diet conditions, particularly in HFD, where insulin secretion was increased, consistent with previous studies 
(57). In addition, obestatin increased islet area in HFD-fed mice, which was reduced as compared with LFD-
fed mice. Thus, together with our previous findings in β cells, human pancreatic islets, and animal models 
of type 1 diabetes (11, 16), these results further support the insulinotropic role of obestatin. 
 
The positive role of obestatin on glucose homeostasis is further sustained by the results obtained in 
adipose tissue explants from HFD-fed mice, where obestatin treatment increased glucose uptake and 
reduced lipolysis. In addition, obestatin increased the number of small, likely insulin-sensitive, adipocytes in 
epididymal and particularly in SC fat of HFD mice. Interestingly, recent studies have shown that increased 
adipocyte cell numbers and overall expansion of SC adipose tissue mass protect against diet-induced insulin 
resistance (60). 
 
Adiponectin is known to improve insulin sensitivity by increasing energy expenditure and fatty acid 
oxidation. Individuals with T2D often exhibit decreased adiponectin levels, and insulin sensitivity is 
improved by adiponectin therapy (31). In HFD-fed mice, obestatin counteracted adiponectin decrease in 
WAT and even increased adiponectin in SC fat from LFD-fed mice, further supporting the positive role of 
obestatin on insulin sensitivity. 
 
Obesity, insulin resistance, and T2D are associated with chronic inflammation and abnormal cytokine 
production, which seems to be triggered by and reside predominantly in adipose tissue. Among 
proinflammatory cytokines that are detrimental to insulin effects are TNF-α and IL-1β, which act in an 
autocrine or paracrine manner to interfere with insulin signaling in peripheral tissues and macrophages (2, 
3). Here, obestatin completely blocked HFD-induced TNF-α increase in WAT, liver, and muscle and similarly 
reduced IL-1β in WAT and liver. Therefore, the alleviated insulin resistance observed in obestatin-treated 
mice fed an HFD may also result from reduced inflammation in peripheral tissues. 
 
Finally, obestatin increased Akt and AMPK phosphorylation in WAT, muscle and liver of HFD-fed mice and 
even increased AMPK activity in LFD-fed mice. Interestingly, in untreated HFD-fed mice, phospho-Akt was 
reduced in epididymal and SC fat, being enhanced in muscle and liver, possibly because of compensatory 
mechanisms or increased insulin levels that stimulated PI3K/Akt signaling. Akt and AMPK play a key role in 
peripheral insulin sensitivity, and their activity is reduced in humans and in animal models of insulin 
resistance (42, 49). Consistent with our findings, decreased AMPK activity has been observed in adipose 
tissue and isolated adipocytes of mice fed an HFD (61), and AMPK activation in mice increases systemic 
insulin sensitivity and protects from HFD-induced obesity and inflammation (49). 
 
Previous results from a single study (20) have reported obestatin effects on adipocytes, which were found 
to be similar to our findings. However, at variance with that study, which only examined mouse and rat 
adipocytes, this study describes obestatin effects in human primary OM and SC adipocytes. Moreover, we 
provide additional evidence of signaling mechanisms triggered by and involved in obestatin metabolic 
effects, such as GLP-1R, which is likely bound by the peptide AMPK, which was previously found not to be 
activated by obestatin (20), and SIRT-1, which is shown here to be involved in obestatin-induced glucose 
uptake. We also first report obestatin effects on adiponectin and leptin secretion in vitro and on inhibition 
of inflammation in vivo. Furthermore, we tested the effects of obestatin in a mouse model of diet-induced 
insulin resistance, providing strong and novel evidence of the positive metabolic role of this peptide. 
Conversely, in the previous studies these aspects were not considered, and, to our knowledge, there is no 
evidence of other studies showing such effects. Therefore, the present study, when compared with others, 
investigates the effects of obestatin in much more in detail not only in vitro; most notably, this is the first 
report showing the effect of obestatin in vivo, using an animal model of insulin resistance. 
 
Overall, our findings suggest a novel role of obestatin in adipocyte function and glucose metabolism. 
Obestatin is produced in mouse and human adipocytes and promotes preadipocyte cell survival and 
influences lipolysis and glucose uptake in vitro. In vivo, obestatin reduces insulin resistance and systemic 
inflammation in HFD-fed mice. Together with our previous findings in the endocrine pancreas, these results 
further indicate the relevant metabolic role of obestatin and suggest potential therapeutic perspectives in 
insulin resistance and metabolic dysfunctions. 
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    hOM 
        human omental 
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        interleukin-1β 
    ISO 
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    ITT 
        insulin tolerance test 
    LFD 
        low fat diet 
    OM 
        omental 
    PI3K 
        phosphoinositide 3-kinase 
    RIA 
        radioimmunoassay 
    SC 
        subcutaneous 
    siRNA 
        small interfering RNA 
    SIRT1 
        sirtuin 1 
    T2D 
        type 2 diabetes 
    TG 
        triglyceride 
    TNF-α 
        tumor necrosis factor α 
    UAG 
        unacylated ghrelin 
    WAT 
        white adipose tissue 
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